News | September 06, 2021
CRAMS to drive growth for Indian pharma industry: report
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
The Bidar API manufacturing facility of Sai Life Sciences has been on a path of significant expansion with its production capacity growing from 200KL in 2017 to 450KL
The company has been sold to Shinshin Pharmaceuticals
This is the third acquisition by Healthium this year apart from AbGel business in India and VitalCare in the UK
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
_256_384.jpg)
As of June 30, 2021, 267 out of a total of 427 SEZs approved by the government are operational
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol
The facility has the capacity to produce one crore doses per day
Subscribe To Our Newsletter & Stay Updated
